COPD ExacerbationNCT03437252
Physical Activity in Chronic Obstructive Pulmonary Disease(COPD) Acute Exacerbation Patients
An observational study of COPD Exacerbation, run by Samsung Medical Center at 1 site in South Korea.
Trial summary
Patients who are suffering from Chronic Obstructive Pulmonary Disease (COPD) had a decreased level of physical activity which is consequentially related to another acute exacerbation event. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- COPD Exacerbation
- How many people
- 86 participants
- Where
- 1 siteSouth Korea
- Study dates
- 6 Nov 2017to Dec 2025
- How long will I take part?
- 13 Weeks
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Based on COPD patients who visited Samsung medical center.
Who may be able to join
- COPD patient who have forced expiratory volume in one second/ forced vital capacity (FEV1/FVC) < 70% by spirometry and those who have not been admitted for acute exacerbation in recent 3 months
Who cannot join
- Those who does not consent or those who have drug addiction, psycho-socially or medically not feasible to this study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Association of Physical Activity With Readmission Due to Exacerbation in COPD Patients
Patients who are suffering from Chronic Obstructive Pulmonary Disease (COPD) had a decreased level of physical activity which is consequentially related to another acute exacerbation event. In this study, we selected patients from those who were admitted for acute exacerbation of COPD, evaluated physical activity by accelerometer (wearable multisensory armband devices) to find out the correlation between physical activity in COPD acute exacerbation patients.
- Conditions
- COPD Exacerbation
- Keywords
- Chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease acute exacerbation, Physical activity, Wearable arm device
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Motor Activity
What is being measured
The primary outcome is the main question the study is designed to answer.
Re admission rate after COPD acute exacerbation
Measured: 13 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2018
- Study start6 Nov 2017
- Primary completion19 Nov 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPD ExacerbationStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 86 participants (estimated)
- Target duration
- 13 Weeks
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hye Yun Park, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03437252
- Sponsor's protocol ID
- 2017-11-009-002
- Status last verified
- Oct 2021
- First submitted
- 13 Feb 2018
- Last updated
- 18 Oct 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association of Physical Activity With Readmission Due to Exacerbation in COPD Patients
- ClinicalTrials.gov ID
- NCT03437252
- Acronym / sponsor ID
- 2017-11-009-002
- Conditions
- COPD Exacerbation
- Keywords
- Chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease acute exacerbation, Physical activity, Wearable arm device
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- Samsung Medical CenterUniversity, hospital or other
- Study start
- 6 Nov 2017 (actual)
- Primary completion
- 19 Nov 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 19 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients who are suffering from Chronic Obstructive Pulmonary Disease (COPD) had a decreased level of physical activity which is consequentially related to another acute exacerbation event. In this study, we selected patients from those who were admitted for acute exacerbation of COPD, evaluated physical activity by accelerometer (wearable multisensory armband devices) to find out the correlation between physical activity in COPD acute exacerbation patients.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
- Target follow-up
- 13 Weeks
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Based on COPD patients who visited Samsung medical center.
Key inclusion criteria (1 listed)
- COPD patient who have forced expiratory volume in one second/ forced vital capacity (FEV1/FVC) < 70% by spirometry and those who have not been admitted for acute exacerbation in recent 3 months
Key exclusion criteria (1 listed)
- Those who does not consent or those who have drug addiction, psycho-socially or medically not feasible to this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Re admission rate after COPD acute exacerbation
Time frame: 13 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2021.
Related trials for COPD Exacerbation
RecruitingObservational study
Characteristics and Outcomes of Patients Admitted to ICU for a Severe Acute Exacerbation of COPD.
COPD Exacerbation, ICU
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Active, not recruitingObservational study
CareCOPD - COPD Home Monitoring Study
Chronic Obstructive Pulmonary Disease
Recruiting
A Prospective Study of Cardiovascular Risk of Patients Admitted for Acute Exacerbation of COPD
COPD
Not yet recruitingPhase 4
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
COPD Exacerbation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COPD Exacerbation, run by Samsung Medical Center at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Re admission rate after COPD acute exacerbation (time frame: 13 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2021.